Technological breakthroughs have continued to bolster medical research and clinical chemistry. Onset of biochip has proved revolutionary in improving patient profiling besides assisting clinicians to develop enhanced diagnostic apparatus to render superlative healthcare across patient pools.

Biochips, otherwise also known as microchips, as the names suggest are extremely tiny, wafer substances that are most often obtained from silicon, quartz, plastic and glass. There are several tested methods to obtain biochips of the highest grade intended for multidisciplinary adoption.

To begin with, microarrays is one such method that employs a highly flat substrate over which sensor components are aligned and fixed on to the substrate surface. Microarrays thus obtained find ample applications in DNA analysis and also in deriving other relevant information encompassing protein, antibody and chemical microarrays development.

Deploying biochip further assists improved microarray development, thus adequately replacing substrate with a biochip instead, thus enabling improved medical profiling of patients. The process in termed Biochip Array technology and finds applications in disease occurrence analysis to leverage apt medical aid.

With surged instances of cancer and tumors globally, reliance on advanced diagnosis is likely to grow multifold, thus adoption of biochips in pursuing preventive diagnosis is also likely to expedite. One of the most challenging tasks in biochip formulation is substrate selection. Adherence to stringent regulatory norms in biochip formulation is crucial to avert non-desirable biological interactions. Hence an ideal biochip substrate need to be inert and demonstrate high surface consistency.

Lab-on-a-chip Segment to Witness Large Scale Adoption in Brain Tumor Therapeutics

Biochips remain indispensable for pursuing advances in NGS (Next Generation Sequencing). Biochips and NGS tactics are crucial in offsetting several biological challenges such as single cell, rare cell and rare molecule analysis. Biochips in tandem with NGS continue to benefit clinical genomics, genetic screening, metagenomics, neuroscience, stem cell, as well as pharmacogenetics. Biochips is he next leap forward in NGS that enables isolation of single cells from heterogeneous biological mass, thus advancing rare bacterium analysis and  other clinical studies.

NSG technology has its limitations such as challenges in analyzing bulk sequencing. To correct this, adoption of biochips is the best logical solution to mediate single cell analysis at high resolutions, besides limiting operational costs. One of the most vital applications of biochips in NSG is in microfluidic single cell separation. Further, laser based single cell separation is yet another application of biochips in NSG.

In terms of further endeavors in biochip space, evolution of lab-on-a-chip format integrates complex laboratory functions on a singular platform, favoring high efficiency and throughput. Market players are continually demonstrating advances in biochip, further exploring novelties in tumor and brain cancer therapeutics. Microfluidic brain cancer chips are revolutionary milestones in assisting drug administration specifically for highly malignant glioblastoma cases. On the basis of tumor spheroids, biochip assists in rendering precise analysis about drug combinations and their efficacy in reversing brain tumors. Developments as such are envisioned to perk up optimistic returns in global biochip market in the near future.